Latin America Intravenous Immunoglobulin Market Size & Outlook
Latin America intravenous immunoglobulin market, 2018-2030 (US$M)
Related Markets
Latin America intravenous immunoglobulin market highlights
- The Latin America intravenous immunoglobulin market generated a revenue of USD 477.9 million in 2024.
- The market is expected to grow at a CAGR of 8% from 2025 to 2030.
- In terms of segment, immunodeficiency diseases was the largest revenue generating application in 2024.
- Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Argentina is expected to register the highest CAGR from 2025 to 2030.
Latin America data book summary
| Market revenue in 2024 | USD 477.9 million |
| Market revenue in 2030 | USD 760.1 million |
| Growth rate | 8% (CAGR from 2025 to 2030) |
| Largest segment | Immunodeficiency diseases |
| Fastest growing segment | Kawasaki Disease |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
| Key market players worldwide | Biotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma |
Other key industry trends
- In terms of revenue, Latin America region accounted for 3.4% of the global intravenous immunoglobulin market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 5,201.7 million by 2030.
Immunodeficiency diseases was the largest segment with a revenue share of 21.09% in 2024. Horizon Databook has segmented the Latin America intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
The Latin American IVIG market is experiencing notable growth, primarily due to rising demand for IVIG therapies to treat conditions such as Kawasaki disease and Myasthenia Gravis. Countries like Brazil are leading this trend, where an increasing number of hospitals and specialty pharmacies are focusing on delivering advanced treatments for immunodeficiency diseases. The presence of key players such as Grifols SA and Baxter is driving market expansion, helping to ensure wider access to IVIG therapies in the region.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Immunoglobulin Market Scope
Intravenous Immunoglobulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Latin America intravenous immunoglobulin market size, by country, 2018-2030 (US$M)
Latin America Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
